This site is intended for healthcare professionals

Five-year data from the SOLO-1 phase III trial is the longest follow-up analysis for any PARP inhibitor in the 1st-line maintenance setting to treat advanced BRCA-mutated ovarian cancer. AstraZeneca + Merck Inc.

Read time: 1 mins
Last updated:28th Jun 2021
Published:19th Sep 2020
Condition: Ovarian Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest